😱 Look at the violent shaking during the M7.8 Mindanao earthquake, captured at Mabila Port on Balut Island in the Philippines a couple of days ago.
It’s hard to imagine what it must have felt like to be there.
⚡️BREAKING: Evacuation has begun at the Pentagon due to a leak of hazardous airborne materials
Pentagon spokesperson Parnell said that internal systems “detected an air quality issue that requires precautionary measures until its severity is determined.”
Several floors of the Pentagon have been evacuated.
you have no idea how much better it is getting
just this week:
- a child was successfully implanted after embryo screening for IQ in the 99.99th percentile. the default human is already being upgraded
- the first ever reverse-aging drug was injected into a human. Life Biosciences by @davidasinclair , so it begins
- Sinclair also announced plans to test an oral reprogramming pill in the $101M XPRIZE. whole-body rejuvenation. a pill you swallow
- Retro Biosciences raised new funding at a $1.8B valuation
- @newlimit announced its first medicines headed to the clinic. Brian Armstrong's $3.1B longevity bet is moving from lab to human
- Junevity published PNAS research validating transcription factor modulation can reverse cellular aging. first-in-human trials starting H2 2026
- retatrutide phase 3 confirmed 70 pounds lost on average. no plateau. bariatric surgery territory from a weekly injection
this is just week one of June 2026
bio/acc
🚨 AI JUST DISCOVERED QUANTUM EFFECTS THAT SCIENTISTS DIDN'T KNOW EXIST.
Researchers at the University of Washington used artificial intelligence to simulate dozens of atomically thin sheets of molybdenum ditelluride stacked in precise twisted patterns.
At small scales, these materials look relatively ordinary. But when the AI modeled much larger stacks, completely new quantum behaviors emerged phenomena that only exist because of the complex, repeating moiré patterns formed across many layers.
Why this matters:
• Many of the most interesting quantum effects only appear at scales that are too large for traditional supercomputers to simulate
• AI can act as a fast “surrogate” that learns from smaller calculations and predicts behavior at much bigger scales
• These large-scale moiré systems can host exotic quantum states useful for quantum computing and new types of electronics
• The same approach could be used to discover many other hidden quantum materials
The deeper implication:
We are entering an era where AI doesn’t just help us analyze data it helps us discover entirely new quantum phenomena that were previously invisible because they only exist in systems too complex for conventional modeling.
This could dramatically speed up the search for materials that power future quantum technologies.
What do you find more exciting using AI to uncover hidden quantum effects in materials, or the possibility that these stacked atomic sheets could become building blocks for future quantum computers?
Follow for more frontier quantum materials and AI-driven discovery.
Chile isn't just focusing on #EV growth. It's also building one of the world's largest renewable energy projects, bolstering #VRE growth.
Oasis de Atacama combines 2 GW of solar with 11 GWh of battery storage, enough to shift vast amounts of daytime solar into evening peak. #SWB
I'm a cardiologist. I need to talk to you about peptides — because the regulatory landscape just shifted dramatically, and most people are getting their information from the worst possible sources.
In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides restricted under the FDA's Category 2 compounding list would be moved toward reclassification. The FDA's Pharmacy Compounding Advisory Committee is scheduled to formally review them on July 23-24 of this year.
If approved, peptides like BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, KPV, and MOTS-C could become legally available through licensed compounding pharmacies with physician prescriptions for the first time since restrictions began.
This is a genuine turning point in regenerative medicine. And it's also the moment when misinformation could do the most damage — because demand has been exploding through gray-market channels for years, and people need both halves of the truth.
Here's the cardiologist's version. No hype. No bro-science. What the data actually shows and what you need to know.
The promise is real.
BPC-157 — a peptide derived from human gastric juice — has shown remarkable preclinical results in tissue repair, gut lining restoration, angiogenesis, and anti-inflammatory signaling. Animal models demonstrate accelerated healing of tendons, ligaments, muscles, and intestinal tissue. The anecdotal reports from physicians and patients are compelling — soft tissue injuries resolving faster, chronic gut issues improving, systemic recovery that's difficult to explain by placebo alone.
TB-500 — thymosin beta-4 — promotes cell migration, reduces inflammation, and supports cartilage and tendon repair. When stacked with BPC-157, the combination is the most discussed regenerative protocol in longevity medicine right now.
GHK-Cu — a copper peptide — shows anti-aging, antioxidant, and tissue-remodeling properties in preclinical studies. Skin, hair, and wound healing applications.
Ipamorelin and CJC-1295 — growth hormone secretagogues that stimulate natural GH pulses rather than flooding the system with exogenous hormone. Sleep quality, recovery, body composition, and muscle preservation are the reported benefits.
KPV — an anti-inflammatory peptide showing promise for gut inflammation, immune modulation, and conditions where standard anti-inflammatories have failed.
The preclinical data across these compounds is genuinely fascinating. The biology is elegant — these are signaling molecules that amplify your body's own repair mechanisms rather than introducing foreign pharmacology.
Now the half nobody wants to hear.
There are no large randomized controlled human trials for any of the recovery and longevity uses driving the current demand. Not one. The preclinical data is promising. The anecdotal evidence is compelling. But the gap between "animal models and case reports" and "proven safe and effective in humans at these doses for these indications" has not been bridged.
The gray market is a genuine hazard. Independent testing of research-grade peptides sold online has found that over 40% of samples from hundreds of vendors failed basic purity or dose standards. Wrong peptide content. Bacterial contamination. Heavy metals. Residual solvents from manufacturing. Endotoxins. When you buy a vial labeled "for research use only" from an unregulated website, you have no guarantee that what's inside matches what's on the label.
Kennedy himself acknowledged this directly — the Category 2 restrictions didn't eliminate demand. They pushed patients toward unregulated sources with no pharmaceutical oversight. The reclassification is partly an attempt to bring these compounds back under quality-controlled compounding with physician supervision.
Side effects are real and underreported. Most peptide content online shows the upside only. In practice: nausea, GI disruption, injection-site reactions, headaches, water retention, joint pain flares, mood changes, and hormonal disruption have all been reported. BPC-157's promotion of angiogenesis — new blood vessel formation — is a double-edged mechanism. It accelerates healing. It could also theoretically feed an existing tumor. Anyone with a cancer history should approach BPC-157 with extreme caution. Growth hormone secretagogues can affect insulin sensitivity and blood sugar regulation — directly relevant to the metabolic health I monitor as a cardiologist.
Reclassification does not mean FDA approval. Even if these peptides move to Category 1, they remain unapproved drugs available only through licensed compounding pharmacies under physician supervision. This is not an invitation to self-dose from internet vendors. The regulatory shift creates a legal pathway for quality-controlled access. It does not validate every protocol circulating on Reddit.
What I'd tell my own patients right now:
Wait for the July PCAC review before starting anything new. The regulatory clarity coming in six weeks could change what's legally available and at what quality standard.
If you're already using peptides, demand certificates of analysis with batch-specific mass spectrometry data and endotoxin testing from your source. If your vendor can't provide this, you're injecting an unknown substance.
Never start a peptide protocol without physician oversight and baseline bloodwork — hormones, liver function, kidney function, fasting insulin, inflammatory markers. Monitor throughout.
If you have any history of cancer, approach angiogenesis-promoting peptides like BPC-157 with extreme caution and discuss the theoretical risk explicitly with your oncologist.
Cycle intelligently. These are not meant for indefinite daily use. The biological signaling works best in targeted courses, not chronic administration.
And never let peptides replace the foundation: sleep 7-9 hours, resistance training, real food, stress management, and the metabolic optimization I write about every week on this platform. Peptides amplify a healthy system. They do not rescue a broken one.
The peptide revolution is real. The biology is fascinating. The regulatory landscape is finally catching up to the demand.
But the difference between a clinical tool and an unregulated gamble is physician supervision, pharmaceutical-grade sourcing, and honest assessment of what the evidence does and doesn't yet support.
Both halves. As always.
Leaked chats and documents showcase the Russian presidential administration’s role in false-flag vandalism attacks and election interference campaigns in Europe and beyond. @OCCRP@DelfiEE@VSquare_Project https://t.co/pQXhFSUWZ9
NEW: Anthropic is walking back Claude Fable 5's policy to covertly degrade performance for competing AI researchers, after facing fierce backlash.
“We’re changing Fable 5’s safeguards for frontier LLM development to make them visible,” Anthropic tells WIRED. “We made the wrong tradeoff and we apologize for not getting the balance right.”
Yann Lecun published the most heretical AI paper of the year.
He opens by arguing Magnus Carlsen isn't good at chess and only gets more unhinged from there.
The Turing Award winner and his co-authors dropped a paper demanding the AI industry abandon its biggest obsession, AGI.
Right now, everyone from Silicon Valley CEOs to politicians assumes AGI is the ultimate goal. A machine that can do everything a human can do.
LeCun argues that this entire concept is a biological illusion.
Humans do not possess "general" intelligence. We are highly specialized biological machines, tuned by evolution simply to survive in the physical world.
We only think our intelligence is "general" because we are completely blind to the millions of cognitive tasks we are incapable of comprehending.
Which brings us to the chess argument.
Magnus Carlsen is the greatest human chess player in history. But compared to a modern computer? He is fundamentally terrible.
Our belief that Carlsen is "good" at chess is pure human-centric bias. He isn't objectively good. He's just better than the rest of us, who are biologically awful at it.
LeCun says we need to stop building AI to mimic human generality.
Instead, he proposes a new North Star: SAI.
Superhuman Adaptable Intelligence.
Instead of trying to build a machine that mimics our flawed, biologically-limited brains, we need to embrace extreme specialization.
SAI is about the speed of adaptation.
It is an intelligence that can learn to exceed humans at any specific, economically important task.
More importantly, it is designed to fill the vast skill gaps where humans are fundamentally incapable.
Things like managing global energy grids in real-time. Or predicting complex molecular structures.
The entire AI industry is obsessed with building a digital reflection in our own image.
LeCun's paper is a brutal wake-up call.
Who is the greatest scientist of all time (in terms of Google Scholar citations)? Is it Einstein? Or Bengio or Hinton?
No.
It is a humble servant of knowledge, Mr. Rachmad of Indonesia, who has had a rather productive publishing period after the launch of ChatGPT
DiffusionGemma is out 🔥
it's compute-bound so 4x faster compared to other Gemma-4 models (1k tok/s on H100) 💨
also great on coding, generate and iterate on any code from 3D generation to front-end ⤵️
US solar generated more electricity than coal during May!
US solar generation rose 17%!
US coal generation fell 11%!
Solar & storage were 91% of new capacity in first quarter.
Solar deployment and manufacturing are vital to the USA.
https://t.co/41Yuyeccrb